The focus is usually on appetite loss, nausea, or constipation
The most frequent side effects include symptoms like nausea, vomiting, and diarrhea
They require coaching support to develop a different relationship with food
This reluctance is likely to be at least partially attributable to the fact that, until recently, all GLP-1RAs were available as subcutaneous (s.c.) injections, given twice daily (exenatide [13]), once daily (lixisenatide [14] and liraglutide [15]), or once weekly (semaglutide [16], dulaglutide [17], and exenatide extended release [18]), a route that may be less preferable to some patients compared with oral administration [1, 19]
When activated, these receptors decrease the amount of dopamine someone feels when eating a hyperpalatable food, a food thats highly addictive due to a high concentration of sodium, salt, or fat